Straits Times Index
3,367.90 +29.33 (+0.88%) S&P 500
5,467.15 -7.94 (-0.15%) Dow
39,129.34 -40.18 (-0.10%) Nasdaq
17,858.08 -21.22 (-0.12%) Bitcoin USD
62,616.87 -124.21 (-0.20%) CMC Crypto 200
1,339.36 -5.15 (-0.38%)
REGN Jul 2024 995.000 call
| Previous close | 66.00 |
| Open | 66.00 |
| Bid | 47.60 |
| Ask | 56.00 |
| Strike | 995.00 |
| Expiry date | 2024-07-19 |
| Day's range | 66.00 - 66.00 |
| Contract range | N/A |
| Volume | |
| Open interest | 4 |
Simply Wall St.Insiders At Regeneron Pharmaceuticals Sold US$26m In Stock, Alluding To Potential Weakness
The fact that multiple Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) insiders offloaded a considerable amount of...
ZacksRegeneron (REGN) Gets Positive CHMP Opinion for Lymphoma Drug
Regeneron (REGN) gets positive CHMP recommendation for odronextamab for the treatment of adults with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma.
BenzingaWhat's Going On With Regeneron Pharmaceuticals Stock On Friday?
On Friday, Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending conditional approval of odronextamab for relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy. Relapsed/refractory (R/R) follicular lymphoma (FL) refers to cases where FL comes back after initial treatment (relapsed) or
